Search

everythinglearnresearchcommunity

for

Search:↓

Certain inhibitors can potentially treat prostate cancer and other hormone-dependent conditions by controlling sex hormone levels in cells.

Synthetic 19-norprogestins promote bone cell growth and function through their non-phenolic metabolites.

Birth control pills and cyproterone acetate can help treat acne in women, especially when linked to hormonal issues.

Newer contraceptives with less androgenic progestins may reduce female hair loss.

New compounds may help treat prostate issues without affecting androgen receptors.

Topical DHEA safely increases skin oil production.

Cyproterone acetate temporarily reduces hair growth in women with idiopathic hirsutism but doesn't change hormone levels.

Bimatoprost treats glaucoma and promotes hair growth, with potential for more medical uses.

Finasteride effectively reduces excess hair in women with certain conditions.

Oral contraceptives with cyproterone acetate improved quality of life for women with PCOS more than those with levonorgestrel.

A new antiandrogen compound was made and its detailed three-dimensional shape was described.

Progesterone significantly reduces neuroblastoma tumor growth without harming healthy cells.

The enzyme system in hair follicles is similar to the liver's and is affected by certain inhibitors.

The new compounds may be more effective and cheaper than current treatments for conditions like baldness.

Testosterone, progesterone, and levonorgestrel change enzyme levels related to fat production in hamster skin, which could affect skin oil and acne.

The 2003 consensus updated PCOS diagnosis criteria and highlighted increased risks of diabetes and heart disease for those affected.

The 2003 consensus updated PCOS diagnosis criteria and linked PCOS to higher risks of diabetes and heart problems, recommending lifestyle changes to lower these risks.

The report concludes that PCOS is mainly a condition of excess male hormones and its definition may change as new information is discovered.

The guideline suggests using specific criteria to diagnose PCOS, recommends various treatments for its symptoms, and advises screening for related health issues.

The document concludes that PCOS is a complex disorder caused by both genetic and environmental factors, affecting women's health in various ways, and requires personalized treatment.

PCOS is a complex condition with major health impacts, needing more research for better diagnosis and treatment.

Polycystic ovary syndrome affects about 6-10% of women, with varying symptoms and the need for standardized global definitions.

PCOS affects a similar percentage of Black and White women in the Southeastern United States.

Polycystic ovary syndrome is found in 6.5% of unselected Caucasian women in Spain.

The European Society of Endocrinology advises individualized long-term management for PCOS, focusing on lifestyle changes, accurate diagnosis, and treatments for associated health risks and symptoms.

The hypothesis suggests that PCOS may start early in life due to genetic and environmental factors, influencing future reproductive and metabolic problems.

Polycystic ovary syndrome costs the U.S. over $4 billion a year, mainly from treating related health issues.

Experts recommend using evidence-based methods to diagnose and treat hirsutism, focusing on symptoms and underlying causes.

PCOS affects about 4% of women in the southeastern U.S. equally across Black and White populations.